|
22 Jul 2021 |
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
|
|
22 Jul 2021 |
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
|
|
22 Jul 2021 |
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases
|
|
22 Jul 2021 |
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
|
|
22 Jul 2021 |
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date
|
|
22 Jul 2021 |
Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors
|
|
22 Jul 2021 |
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
|
|
22 Jul 2021 |
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
|
|
22 Jul 2021 |
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
|
|
22 Jul 2021 |
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
|
|
22 Jul 2021 |
VERQUVO® (vericiguat) Approved in the European Union
|
|
22 Jul 2021 |
IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
|
|
22 Jul 2021 |
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
|
22 Jul 2021 |
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
|
|
22 Jul 2021 |
Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy
|
|
22 Jul 2021 |
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer
|
|
21 Jul 2021 |
NanoSyrinx raises £6.2m to develop its synthetic biology platform for targeted intracellular engineering
|
|
21 Jul 2021 |
NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes
|
|
21 Jul 2021 |
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
|
|
21 Jul 2021 |
EMA starts rolling review of COVID-19 vaccine Vidprevtyn
|
